Whole-brain radiation therapy for brain metastases: detrimental or beneficial?

Radiation Oncology

Gokhan Yaprak¹  Cengiz Gemici¹ 

[1] Department of Radiation Oncology, Dr. Lutfi Kirdar Kartal Education and Research Hospital, Cevizli, Istanbul, Turkey

关键词: Stereotactic radiosurgery;    Whole-brain radiation therapy;    Brain metastases;   

Others  :  1228492
DOI  :  10.1186/s13014-015-0466-9

 received in 2015-05-10, accepted in 2015-07-16,  发布年份 2015

【 摘 要 】

Stereotactic radiosurgery is frequently used, either alone or together with whole-brain radiation therapy to treat brain metastases from solid tumors. Certain experts and radiation oncology groups have proposed replacing whole-brain radiation therapy with stereotactic radiosurgery alone for the management of brain metastases. Although randomized trials have favored adding whole-brain radiation therapy to stereotactic radiosurgery for most end points, a recent meta-analysis demonstrated a survival disadvantage for patients treated with whole-brain radiation therapy and stereotactic radiosurgery compared with patients treated with stereotactic radiosurgery alone. However the apparent detrimental effect of adding whole-brain radiation therapy to stereotactic radiosurgery reported in this meta-analysis may be the result of inhomogeneous distribution of the patients with respect to tumor histologies, molecular histologic subtypes, and extracranial tumor stages between the groups rather than a real effect. Unfortunately, soon after this meta-analysis was published, even as an abstract, use of whole-brain radiation therapy in managing brain metastases has become controversial among radiation oncologists. The American Society of Radiation Oncology recently recommended, in their “Choose Wisely” campaign, against routinely adding whole-brain radiation therapy to stereotactic radiosurgery to treat brain metastases. However, this situation creates conflict for radiation oncologists who believe that there are enough high level of evidence for the effectiveness of whole-brain radiation therapy in the treatment of brain metastases.

【 授权许可】

   
2015 Gemici and Yaprak.

【 参考文献 】

• [1]Aoyama H, Tago M, Kato N et al.. Neurocognitive function of patients with brain metastasis who received either whole brain radiotherapy plus stereotactic radiosurgery or radiosurgery alone. Int J Radiat Oncol Biol Phys. 2007; 68:1388-1395.
• [2]Chang EL, Wefel JS, Hess KR et al.. Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: A randomized controlled trial. Lancet Oncol. 2009; 10:1037-1044.
• [3]Soffietti R, Kocher M, Abacioglu UM et al.. A European organisation for research and treatment of cancer phase III trial of adjuvant whole-brain radiotherapy versus observation in patients with One to three brain metastases from solid tumors after surgical resection or radiosurgery: quality-of-life results. J Clin Oncol. 2013; 31:65-72.
• [4]Gemici C. Progression-free survival benefit or health-related quality of life advantage; which one to choose? J Clin Oncol. 2013; 31:2635-2636.
• [5]Sahgal A, Aoyama H, Kocher M et al.. Phase 3 trials of stereotactic radiosurgery with or without whole-brain radiation therapy for 1 to 4 brain metastases: Individual patient data meta-analysis. Int J Radiat Oncol Biol Physc. 2015; 91:710-717.
• [6]Sahgal A, Larson D, Knisely J. Stereotactic radiosurgery alone for brain metastases. Lancet Oncol. 2015; 16:249-250.
• [7]Serizawa T, Higuchi Y, Nagano O, Hirai T, Ono J, Saeki N et al.. Testing different brain metastasis grading systems in stereotactic radiosurgery: Radiation Therapy Oncology Group’s RPA, SIR, BSBM, GPA, and modified RPA. J Neurosurg. 2012; 117:31-37.
• [8]Barnholtz-Sloan JS, Yu C, Sloan AE, Vengoechea J, Wang M, Dignam JJ et al.. A nomogram for individualized estimation of survival among patients with brain metastasis. Neuro Oncol. 2012; 14:910-918.
• [9]Chaichana KL, Gadkaree S, Rao K, Link T, Rigamonti D, Purtell M et al.. Patients undergoing surgery of intracranial metastases have different outcomes based on their primary pathology. Neurol Res. 2013; 35:1059-1069.
• [10]Shen Q, Sahin AA, Hess KR et al.. Breast cancer with brain metastases: clinicopathologic features, survival, and paired biomarker analysis. Oncologist. 2015; 20:466-473.
• [11]Kocher M, Soffietti R, Abacioglu UM et al.. Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952–26001 study. J Clin Oncol. 2011; 29:134-141.
• [12]Aoyama H, Shirato H, Tago M et al.. Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial. JAMA. 2006; 295:2483-2491.
• [13]Patchell RA, Tibbs PA, Regine WF et al.. Postoperative radiotherapy in the treatment of single metastases to the brain: a randomized trial. JAMA. 1998; 280:1485-1489.
• [14]De Meerleer G, Khoo V, Escudier B et al.. Radiotherapy for renal-cell carcinoma. Lancet Oncol. 2014; 15:e170-e177.
• [15]Gemici C, Yaprak G. In regard to Sahgal et al. Int J Radiat Oncol Biol Phys. 2015; 92:947-948.
• [16]Sahgal A, Kocher M, Tago M et al.. In reply to Gemici and Yaprak and Lowrey and Marcus. Int J Radiat Oncol Biol Phys. 2015; 92:948-949.
• [17]Gondi V, Pugh SL, Tome WA et al.. Preservation of memory with conformal avoidance of the hippocampal neural stem-cell compartment during whole-brain radiotherapy for brain metastases (RTOG 0933): a phase II multi-institutional trial. J Clin Oncol. 2014; 32:3810-3816.
• [18]Brown PD, Pugh S, Laack NN et al.. Memantine for the prevention of cognitive dysfunction in patients receiving whole-brain radiotherapy: a randomized, double-blind, placebo-controlled trial. Neuro Oncol. 2013; 15:1429-1437.